 |
Lee Woo-hyun, Chairman of OCI Holdings. (Photo = OCI Holdings) |
[Alpha Biz= Reporter Kim Jisun] OCI Holdings announced on August 8 that it has canceled its stock trading and in-kind investment contract with Hanmi Science, the holding company of Hanmi Pharmaceutical Group.
The company also withdrew its decision to increase capital by issuing new stocks under the contract.
On January 12, OCI Holdings and Hanmi Pharmaceutical Group agreed to merge and signed a contract with each other through investment in kind and acquisition of new shares.
OCI Holdings will acquire a 27.0% stake in Hanmi Science, including old shares and 18.6% investment in kind and 8.4% issuance of new shares, while major shareholders of Hanmi Science, including Vice Chairman Lim Joo-hyun, will acquire a 10.4% stake in OCI Holdings.
However, the process of integrating the two companies was suspended after five figures from the founders' first and second sons, Lim Jong-yoon and Jong-hoon, who opposed the merger, were appointed as board members at the regular shareholders' meeting of Hanmi Science on the 28th of last month.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
